Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
Trial · NCT04852679
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Benefit Rate (CBR) of Tumour Response Assessed by Blinded Independent Central Review (BICR) at Week 24 | Lanreotide Autogel 120 mg | 62.79 | 95% Confidence Interval 46.7 to 77.0 | percentage of participants | |
| Progression Free Survival (PFS) by BICR Within Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 24 | NA | 95% Confidence Interval 24.1 to NA | weeks |
| Progression Free Survival (PFS) by BICR Within Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 48 | NA | 95% Confidence Interval 36.1 to NA | weeks |
| Overall Survival (OS) at the End of the Main Intervention Period | Lanreotide Autogel 120 mg | NA | 95% Confidence Interval NA to NA | weeks | |
| Time to Progression (TTP) During Main Intervention Period | Lanreotide Autogel 120 mg | NA | 95% Confidence Interval 48.0 to NA | weeks | |
| Percentage of Participants Alive and Without Tumour Progressive at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 24 | 77.4 | 95% Confidence Interval 59.6 to 88.1 | percentage of participants |
| Percentage of Participants Alive and Without Tumour Progressive at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 48 | 59.0 | 95% Confidence Interval 36.1 to 76.1 | percentage of participants |
| Clinical Benefit Rate Assessed by BICR at Week 48 | Lanreotide Autogel 120 mg | 58.1 | 95% Confidence Interval 42.1 to 73.0 | percentage of participants | |
| Overall Response Rate (ORR) at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 24 | 0 | 95% Confidence Interval 0.0 to 8.2 | percentage of participants |
| Overall Response Rate (ORR) at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 48 | 7.0 | 95% Confidence Interval 1.5 to 19.1 | percentage of participants |
| Disease Control Rate (DCR) at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 24 | 69.8 | 95% Confidence Interval 53.9 to 82.8 | percentage of participants |
| Disease Control Rate (DCR) at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 48 | 69.8 | 95% Confidence Interval 53.9 to 82.8 | percentage of participants |
| Number of Participants With Neuroendocrine Tumours (NET)-Related Clinical Symptoms at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 24: Diarrhea / Grade 1 | 0 | Participants | |
| Number of Participants With Neuroendocrine Tumours (NET)-Related Clinical Symptoms at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 24: Diarrhea / Grade 2 | 0 | Participants | |
| Number of Participants With Neuroendocrine Tumours (NET)-Related Clinical Symptoms at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 24: Diarrhea / Grade 3 | 0 | Participants | |
| Number of Participants With Neuroendocrine Tumours (NET)-Related Clinical Symptoms at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 24: Diarrhea / Grade 4 | 0 | Participants | |
| Number of Participants With Neuroendocrine Tumours (NET)-Related Clinical Symptoms at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 24: Diarrhea / Grade 5 | 0 | Participants | |
| Number of Participants With Neuroendocrine Tumours (NET)-Related Clinical Symptoms at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 24: Diarrhea / Missing | 43 | Participants | |
| Number of Participants With Neuroendocrine Tumours (NET)-Related Clinical Symptoms at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 48: Diarrhea / Grade 1 | 0 | Participants | |
| Number of Participants With Neuroendocrine Tumours (NET)-Related Clinical Symptoms at Weeks 24 and 48 | Lanreotide Autogel 120 mg | Week 48: Diarrhea / Grade 2 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04852679/results